147 related articles for article (PubMed ID: 9551707)
1. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.
Stern RH; Gibson DM; Whitfield LR
Eur J Clin Pharmacol; 1998 Feb; 53(6):475-8. PubMed ID: 9551707
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.
Whitfield LR; Stern RH; Sedman AJ; Abel R; Gibson DM
Eur J Drug Metab Pharmacokinet; 2000; 25(2):97-101. PubMed ID: 11112089
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
4. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Stern RH; Yang BB; Horton M; Moore S; Abel RB; Olson SC
J Clin Pharmacol; 1997 Sep; 37(9):816-9. PubMed ID: 9549635
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.
Cilla DD; Gibson DM; Whitfield LR; Sedman AJ
J Clin Pharmacol; 1996 Jul; 36(7):604-9. PubMed ID: 8844442
[TBL] [Abstract][Full Text] [Related]
7. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
8. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.
Radulovic LL; Cilla DD; Posvar EL; Sedman AJ; Whitfield LR
J Clin Pharmacol; 1995 Oct; 35(10):990-4. PubMed ID: 8568017
[TBL] [Abstract][Full Text] [Related]
9. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
11. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
14. Erythromycin coadministration increases plasma atorvastatin concentrations.
Siedlik PH; Olson SC; Yang BB; Stern RH
J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence study of atorvastatin tablets.
Koytchev R; Ozalp Y; Erenmemisoglu A; van der Meer MJ; Alpan RS
Arzneimittelforschung; 2004 Sep; 54(9A):573-7. PubMed ID: 15497662
[TBL] [Abstract][Full Text] [Related]
16. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Andrén L; Andreasson A; Eggertsen R
Eur J Clin Pharmacol; 2007 Oct; 63(10):913-6. PubMed ID: 17701167
[TBL] [Abstract][Full Text] [Related]
17. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects.
Tippabhotla SK; Betha MR; Gadiko C; Battula R; Nakkawar M; Cheerla R; Khan SM; Yergude S; Thota S; Vobalaboina V
Drug Res (Stuttg); 2013 May; 63(5):250-7. PubMed ID: 23526241
[TBL] [Abstract][Full Text] [Related]
19. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
